Onco Actu du 18 décembre 2017

	3.1 Prévention - Tabac
Tobacco industry trumps as India court cancels stringent health labeling rules [Reuters] Similar battles between tobacco companies and authorities have played out around the world in recent years as governments try to discourage smoking. India’s tobacco packaging rules were among the world’s most stringent and aimed at reducing tobacco consumption which kills more than 900,000 people a year.
	4.12 Biopsies liquides
Grail taps Genentech vet Jennifer Cook as CEO, building expectations for 2018 [EndPoints] Grail is starting out in Asia with a screening test for nasopharyngeal cancer, a prevalent disease in Southern China and Southeast Asia. The first launch is planned in Hong Kong, where the company has a collaboration with a local university.
	5.10 Traitements - Essais
Cancer clinical trials exclude many desperate patients. Should that change? [Washington Post] Gerber, the lead author of the study, says the increase reflects the general practice of adding new criteria that are relevant to contemporary treatments, such as immunotherapies and targeted therapies, without removing criteria that are not pertinent to these drugs.
	5.12 Immunothérapies
Tumor Mutational Burden and Response to Immune Checkpoint Therapy [Rutgers] Researchers at Rutgers Cancer Institute of New Jersey examined an association between mutational burden and response to immune checkpoint therapy in several cancer types and found that a mutational burden threshold exists in eight cancers that predict response to an immune checkpoint blockade.
	5.12.1 Immunothérapies - partenariats
Regeneron and ISA Pharmaceuticals announce strategic immuno-oncology collaboration [Regeneron] Regeneron and ISA will jointly fund and conduct clinical trials of the combination treatment in cervical cancer and head-and-neck cancer.
	5.12.2 Immunothérapies - CAR-T
Is Gilead’s new CAR-T overpriced or is payer bureaucracy to blame for slow pickup? [FiercePharma] There is one prediction, however, that can be made with confidence: The full launch of Yescarta will take longer than Wall Street analysts had predicted.
	5.2 Pharma
Novartis loses top oncology executive Strigini to retirement [FiercePharma] Just before Strigini joined Novartis, the company agreed to its massive asset swap with GSK, offloading its vaccine programs—besides flu—in exchange for Glaxo's cancer offerings. Outgoing Novartis CEO Joe Jimenez called the deal "transformational" when it was announced as it would ultimately propel the drugmaker to a leadership position in oncology.
	5.2.1 Pharma - Partenariats
Cancer Research UK announces drug discovery collaboration with Celgene Corporation [Cancer Research UK] This arrangement represents an expansion of Cancer Research Technology’s theme-based translational model that now encompasses six industry partnerships, including this new collaboration with Celgene.
	5.3 Traitements - FDA, EMA, NICE...
EU drugs agency says move to new HQ may take longer [Reuters] A spokeswoman for the city of Amsterdam on Friday said there had been no change in its plans for EMA. She said, the building will be completed in two stages and should be ready to accommodate all employees at the beginning of 2020 as promised.
Statement from FDA Commissioner Scott Gottlieb, M.D., on new FDA efforts to support more efficient development of targeted therapies [FDA] These scientific principles described in the guidance could also be applied to supporting “tissue agnostic” drug development. This relates to how drugs may be able to gain regulatory approval on the basis of targeting a molecular subtype that is common across different phenotypes, rather than solely on the individual disease states.
	5.3.4 Traitements - AMM (FDA, EMA)
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2017 [EMA] One biosimilar medicine was recommended for approval by the Committee: Herzuma (trastuzumab), for the treatment of breast and gastric cancer. The Committee recommended extensions of indications for Taltz, Truvada and Yervoy.
	5.4 Traitements - Economie
New PARP inhibitor hits UK market, offering distinct advantage [Pharmafile] The next step for Zejula is to go in-front of NICE to determine whether the treatment is cost-effective enough to be covered by the NHS and provided to the wider population.
Drug that holds back return of ovarian cancer gets UK licence [The Guardian] The drug is now licensed for use in the UK but is yet to be assessed for free availability on the NHS.
	6. Lutte contre les cancers
NCI: Taking Risks to Advance Science [NCI] Currently, we are very good at describing the stage, pathology, and specific molecular features of a cancer. Yet, we still aren’t sufficiently adept at telling patients what they really want to know: what treatment will work given the underlying biology of their tumor. And that is very frustrating to both patients and clinicians.
Coalition Seeks to Increase Transparency on Life Science Career Prospects [Johns Hopkins] Nine U.S. research universities and a major cancer institute today announced plans to give would-be life scientists clear, standardized data on graduate school admissions, education and training opportunities, and career prospects.
	6.1 Observation
Science Surgery: ‘Does having had cancer make you more likely to develop it again?’ [Cancer Research UK] Moorman says that while second cancers have been recognised for some time, the risk is still very small. A recent study carried out in Denmark found that the risk of cancer developing in people who have had cancer before was only 1.1 times greater than people who have no history of cancer.
	6.10.1 Politiques (USA)
CDC director tells staff ‘there are no banned words,’ while not refuting report [STAT] A Health and Human Services official who asked not to be named told STAT it was not accurate to say that CDC had been ordered not to use the seven words. Instead, he said, agency budget analysts were told that some words and phrasing might be more likely to win support for the CDC’s budget in the current Congress.
The seven dirty words the CDC won’t be able to say any more [Science-Based Medicine] On Saturday, the Washington Post broke a story that Trump administration will prohibit officials at the CDC from using a list of seven words or phrases — including “transgender,” “evidence-based,” and “science-based” — in official documents being prepared for next year’s budget.
	6.11 Patients
Voices: Learning to Accept (if Not Love) My Scar [NY Times] Let’s face it: Nothing breaks the mood like announcing: “Hey, I have a really big scar because I had cancer!” After a few awkward test-drives with boyfriend-candidates, I chose to be celibate for a couple of years.